Abstract: Pharmacological treatment of inflammatory bowel disease (IBD) is inefficient and difficult to discontinue appropriately, and enterobacterial interactions are expected to provide a new target for the treatment of IBD. We collected recent studies on the enterobacterial interactions among the host, enterobacteria, and their metabolite products and discuss potential therapeutic options. Intestinal flora interactions in IBD are affected in the reduced bacterial diversity, impact the immune system and are influenced by multiple factors such as host genetics and diet. Enterobacterial metabolites such as SCFAs, bile acids, and tryptophan also play important roles in enterobacterial interactions, especially in the progression of IBD. Therapeutically, a wide range of sources of probiotics and prebiotics exhibit potential therapeutic benefit in IBD through enterobacterial interactions, and some have gained wide recognition as adjuvant drugs. Different dietary patterns and foods, especially functional foods, are novel therapeutic modalities that distinguish pro-and prebiotics from traditional medications. Combined studies with food science may significantly improve the therapeutic experience of patients with IBD. In this review, we provide a brief overview of the role of enterobacteria and their metabolites in enterobacterial interactions, discuss the advantages and disadvantages of the potential therapeutic options derived from such metabolites, and postulate directions for further research.
Introduction
Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, represents a significant global health burden with a steadily rising incidence. Current pharmacological strategies, primarily relying on biologics and immunosuppressants, often face challenges regarding long-term efficacy and significant side effects. Furthermore, clinicians frequently encounter a "dilemma of drug withdrawal," where patients experience rapid relapse upon cessation of treatment.
This review, published in Frontiers in Microbiology, argues for a paradigm shift. Rather than focusing solely on immune suppression, effective treatment may lie in understanding and manipulating the enterobacterial interaction: the complex, tripartite dialogue between host genetics, the gut microbiota, and microbial metabolites (the "gut metabolome") that maintains intestinal homeostasis.
Drivers of Dysbiosis and Microbial Signatures
IBD is fundamentally characterized by a breakdown in microbial diversity. Metagenomic data consistently reveals a reduction in beneficial Clostridium clusters IV and XIVa and an expansion of opportunistic Proteobacteria, such as Escherichia coli. These shifts are not random but are driven by a combination of host genetics and environmental stressors.
Specific genetic polymorphisms, such as those in NOD2 and ATG16L1, have been linked to impaired microbial handling and altered gut composition. Research has shown that deficiencies in these pathways can lead to the overgrowth of specific pathogens or the loss of protective species like Akkermansia, which are vital for maintaining the mucosal barrier.
The Gut Metabolome: Chemical Signaling in Homeostasis
A central theme of recent research is the role of metabolites as "immune rheostats." These small molecules are not merely metabolic waste but act as critical signaling ligands that modulate host immunity.
Short-Chain Fatty Acids (SCFAs)
SCFAs like acetate, propionate, and butyrate are produced through the fermentation of dietary fiber. They bind to G-protein-coupled receptors (e.g., GPR43) to suppress pro-inflammatory cytokines and enhance the physical gut barrier by promoting the expression of tight junction proteins. Clinical trials have demonstrated that 30-day sodium butyrate enemas can significantly improve endoscopic scores and promote mucosal repair in ulcerative colitis patients.
Bile Acid Metabolism
IBD patients typically exhibit a shift in bile acid profiles, characterized by an increase in primary bile acids (PBAs) and a decrease in secondary bile acids (SBAs). This shift is significant because SBAs normally activate FXR and TGR5 receptors, which inhibit pro-inflammatory NF-κB signaling and promote the regeneration of intestinal stem cells.
Tryptophan and the AhR Pathway
Tryptophan metabolites serve as essential ligands for the Aryl Hydrocarbon Receptor (AhR). Activation of the AhR pathway is critical for the survival of intraepithelial lymphocytes and the production of IL-22, a cytokine vital for repairing the intestinal mucosa.
Therapeutic Frontiers: Probiotics, Postbiotics, and Diet
The understanding of these interactions has paved the way for novel therapeutic modalities. Probiotic cocktails, such as "Visbiome," have shown promise, achieving a 56.2% remission rate in active ulcerative colitis in some clinical cohorts.
However, the review highlights the emergence of "postbiotics"—inanimate microorganisms or their components/metabolites—as a potentially safer and more stable alternative to live probiotics. Postbiotics offer the functional benefits of beneficial bacteria without the risk of introducing live strains into an already inflamed and unstable environment.
Dietary intervention remains a cornerstone of management. While "Western" high-fat diets are linked to lipid overload and focal inflammation, Mediterranean-style diets have been shown to reduce systemic inflammation markers like C-reactive protein (CRP) and fecal calprotectin.
Challenges and Future Directions
Despite these insights, several hurdles remain. Much of our mechanistic understanding is derived from animal models, such as DSS-induced colitis, which may not fully replicate the chronic nature of human IBD. Furthermore, the high degree of heterogeneity in the human gut microbiota—where even identical twins share only a fraction of microbial strains—makes "one-size-fits-all" therapies difficult to implement.
Future research must address the "dark matter" of the gut, including the virome (viruses) and mycobiome (fungi), and develop more sophisticated delivery systems to ensure that postbiotics and engineered probiotics reach the colon in an active, stable form. Personalizing these interventions based on a patient's unique microbial and metabolic profile will be the next frontier in IBD care.
Summary updated